Publications by authors named "Elisa Gomez Valderas"
Objective: This prospective study aimed to describe the clinical course in terms of glycemic outcomes, body weight, and adverse events during the first 12 weeks following a switch from glucagon-like peptide-1 receptor agonists (GLP-1 RAs) directly to tirzepatide 5 mg.
Methods: Participants were ≥18 years with type 2 diabetes (T2D), glycated hemoglobin (HbA1c) ≥6.5% to ≤9.
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Diabetes Obes Metab
April 2023
Aim: To assess composite endpoints combining glycaemic control (HbA1c < 7.0%, ≤ 6.5% or < 5.
View Article and Find Full Text PDFArticle Synopsis
- Mirikizumab, a monoclonal antibody targeting interleukin 23p19, shows promise in treating moderate-to-severe Crohn's disease (CD), with demonstrated effectiveness in earlier studies on psoriasis and ulcerative colitis.
- In a study with 191 patients, those receiving mirikizumab had a significantly better endoscopic response at Week 12 compared to placebo, particularly at the 600 mg and 1000 mg doses.
- Safety profiles for mirikizumab were comparable to placebo, although there were higher rates of serious adverse events in certain nonrandomized groups, indicating the necessity for careful monitoring.
Background: A significant proportion of triptan users exhibit an insufficient response or inadequate tolerability to a triptan, and some may develop a contraindication. Lasmiditan, a selective 5-HT receptor agonist, may be an option for these individuals. We assessed lasmiditan efficacy in a subgroup of patients in CENTURION (Phase 3 migraine consistency study) who exhibited an insufficient response to triptans, including a subgroup with insufficient response due to efficacy only.
View Article and Find Full Text PDF